Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • sthor
    Junior Member
    • Nov 2014
    • 1

    #31
    Passenger versus Driver

    Hi,

    how do you interprete the oncofuse output based on the definitions below?

    low P_VAL_CORR => likely passenger?
    high DRIVER_PROB => likely driver?
    EXPRESSION_GAIN => how are 5'/3' expressions computed?

    I have these two lines for instance which seem contradictory:
    1130 0 KDR Yes Exon 6 1 1138 2 2 5.616331914947E-5 0.9999999839119682 0.7550226777191273 Pleckstrin homology-like domain[Domain];Arf GTPase activating protein[Family];Pleckstrin homology domain[Domain];Arfaptin homology (AH) domain/BAR domain[Domain];Src homology-3 domain[Domain];Ankyrin repeat-containing domain[Domain];Ankyrin repeat[Repeat] Immunoglobulin-like domain[Domain];Immunoglobulin subtype 2[Domain];Immunoglobulin subtype[Domain];Serine-threonine/tyrosine-protein kinase catalytic domain[Domain];Immunoglobulin-like fold[Domain];Protein kinase, ATP binding site[Binding_site];Tyrosine-protein kinase, receptor class III, conserved site[Conserved_site];Immunoglobulin I-set[Domain];Tyrosine-protein kinase, active site[Active_site];Protein kinase-like domain[Domain];Immunoglobulin V-set domain[Domain];Tyrosine-protein kinase, catalytic domain[Domain];Protein kinase domain[Domain];Vascular endothelial growth factor receptor 2 (VEGFR2)[Family] GRB2;SRC KDR;NCK1;PLCG1;PTPN6;SHC1;SRC;VEGFA;VEGFC;NRP1;SH2D2A;SHC2;FLT4;FYN;GRB2;GRB10 0.031693123551895894 0.060912399971582896 0.0011108580362268734 0.08982267991811016 0.03377877733466933 0.01758896057545965
    679 0 CLTC Yes Exon 10 31 1159 0 0 4.159324576929766E-4 0.9999996425673524 -0.33165129627027434 Zinc finger, C2H2-like[Domain] Clathrin, heavy chain/VPS, 7-fold repeat[Repeat];Clathrin, heavy chain[Family];Tetratricopeptide-like helical[Domain];Armadillo-type fold[Domain] Zinc finger, C2H2-like[Domain] CLTC;CLTA;CLTB 0.00561979753630853 0.0 3.7249030480169165E-5 0.0 0.0011034671362001604 0.018050986438399443


    P_VAL_CORR

    The Bayesian probability of fusion being a passenger (class 0), given as Bonferroni-corrected P-value.
    DRIVER_PROB

    The Bayesian probability of fusion being a driver (class 1).
    EXPRESSION_GAIN

    Expression gain of fusion calculated as:

    [(expression of 5' gene)/(expression of 3' gene)]-1

    Thanks,

    Comment

    • mikesh
      Member
      • Jul 2012
      • 29

      #32
      Originally posted by sthor View Post
      Hi,

      how do you interprete the oncofuse output based on the definitions below?

      low P_VAL_CORR => likely passenger?
      high DRIVER_PROB => likely driver?
      EXPRESSION_GAIN => how are 5'/3' expressions computed?

      I have these two lines for instance which seem contradictory:
      1130 0 KDR Yes Exon 6 1 1138 2 2 5.616331914947E-5 0.9999999839119682 0.7550226777191273 Pleckstrin homology-like domain[Domain];Arf GTPase activating protein[Family];Pleckstrin homology domain[Domain];Arfaptin homology (AH) domain/BAR domain[Domain];Src homology-3 domain[Domain];Ankyrin repeat-containing domain[Domain];Ankyrin repeat[Repeat] Immunoglobulin-like domain[Domain];Immunoglobulin subtype 2[Domain];Immunoglobulin subtype[Domain];Serine-threonine/tyrosine-protein kinase catalytic domain[Domain];Immunoglobulin-like fold[Domain];Protein kinase, ATP binding site[Binding_site];Tyrosine-protein kinase, receptor class III, conserved site[Conserved_site];Immunoglobulin I-set[Domain];Tyrosine-protein kinase, active site[Active_site];Protein kinase-like domain[Domain];Immunoglobulin V-set domain[Domain];Tyrosine-protein kinase, catalytic domain[Domain];Protein kinase domain[Domain];Vascular endothelial growth factor receptor 2 (VEGFR2)[Family] GRB2;SRC KDR;NCK1;PLCG1;PTPN6;SHC1;SRC;VEGFA;VEGFC;NRP1;SH2D2A;SHC2;FLT4;FYN;GRB2;GRB10 0.031693123551895894 0.060912399971582896 0.0011108580362268734 0.08982267991811016 0.03377877733466933 0.01758896057545965
      679 0 CLTC Yes Exon 10 31 1159 0 0 4.159324576929766E-4 0.9999996425673524 -0.33165129627027434 Zinc finger, C2H2-like[Domain] Clathrin, heavy chain/VPS, 7-fold repeat[Repeat];Clathrin, heavy chain[Family];Tetratricopeptide-like helical[Domain];Armadillo-type fold[Domain] Zinc finger, C2H2-like[Domain] CLTC;CLTA;CLTB 0.00561979753630853 0.0 3.7249030480169165E-5 0.0 0.0011034671362001604 0.018050986438399443


      P_VAL_CORR

      The Bayesian probability of fusion being a passenger (class 0), given as Bonferroni-corrected P-value.
      DRIVER_PROB

      The Bayesian probability of fusion being a driver (class 1).
      EXPRESSION_GAIN

      Expression gain of fusion calculated as:

      [(expression of 5' gene)/(expression of 3' gene)]-1

      Thanks,
      Hello!

      DRIVER_PROB means the probability (in Bayesian sense) of being a driver mutation.

      The same in represented by P-value, the probability of being a passanger, with one major difference. P_VAL_CORR = FDR(1-DRIVER_PROB), where FDR represents Benjamini-Hochberg corrected P-values.

      Expression gain is calculated based on gene expression values in normal tissue, according to library option. The corresponding routine uses the gene expression data provided with Oncofuse bundle.

      So both of them are putative drivers, with promoter swapping being possible mechanism in the first case.

      ---

      PS
      Just in case, I'm adding the link to source code repository of Oncofuse containing the latest release: https://github.com/mikessh/oncofuse
      Last edited by mikesh; 11-24-2014, 09:11 AM.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      37 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-13-2026, 09:56 AM
      0 responses
      31 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-09-2026, 11:14 AM
      0 responses
      29 views
      0 reactions
      Last Post SEQadmin2  
      Working...